다우존스 지수

브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.

등록

홈
인베스팅
주식
미국
NASDAQ
Esperion Therapeutics Inc (ESPR)
Esperion Therapeutics Inc (ESPR) 뉴스

ESPR

Esperion Therapeutics (ESPR)

Esperion Therapeutics Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:ESPR

1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/05/14	21:00	GlobeNewswire Inc.	Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET®	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/05/11	05:00	GlobeNewswire Inc.	Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/05/09	05:31	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/05/07	21:50	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/05/07	20:29	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/05/07	19:00	GlobeNewswire Inc.	Esperion Reports First Quarter 2024 Financial Results	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/04/29	21:00	GlobeNewswire Inc.	Esperion to Participate in Upcoming May Investor Conferences	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/04/23	21:00	GlobeNewswire Inc.	Esperion to Report First Quarter 2024 Financial Results on May 7	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/04/08	03:45	GlobeNewswire Inc.	Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/04/01	21:00	GlobeNewswire Inc.	Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/03/26	21:00	GlobeNewswire Inc.	Esperion to Participate in 23rd Annual Needham Virtual Healthcare Conference	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/03/26	05:00	GlobeNewswire Inc.	Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/03/23	07:26	Business Wire	U.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/03/23	04:10	GlobeNewswire Inc.	U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/03/23	00:04	GlobeNewswire Inc.	CHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular Events	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/02/27	23:19	Edgar (US Regulatory)	Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/02/27	21:23	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/02/27	20:00	GlobeNewswire Inc.	Esperion Reports Fourth Quarter and Full Year 2023 Financial Results	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/02/17	06:30	GlobeNewswire Inc.	Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/02/15	04:14	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/02/15	00:50	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/02/14	22:42	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/02/14	20:11	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/02/13	22:00	GlobeNewswire Inc.	Esperion to Report Fourth Quarter and Full Year 2023 Financial Results on February 27	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/02/02	04:00	GlobeNewswire Inc.	RFK, Esperion Therapeutics Announce 2024 Promotional Schedule	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/01/24	06:00	GlobeNewswire Inc.	Esperion Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/01/22	20:10	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/01/22	20:04	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/01/19	11:15	GlobeNewswire Inc.	Esperion Announces Pricing of $85.1 Million Public Offering of Common Stock	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/01/19	06:03	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ESPR	Esperion Therapeutics Inc

검색 관련기사 보기:NASDAQ:ESPR

1 2 3 4 5 6 7 8 9 10 다음 >>

BNP Paribas (QX)

Financial Select Sector

Gold vs US Dollar

Deutsche Telekom (QX)

US Dollar vs Yen

Verizon Communications

Bank of America

Energy Select Sector SPDR

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관